Alzheimer's disease
Conditions
Interventions
experimental group:Astaxanthin tablets (6mg astaxanthin/tablet), taken orally, 1 tablet each time in the morning and evening.
placebo control group:Simulated astaxanthin tablets, taken orally, 1 tablet each time in the morning and evening. The course of treatment is 12 weeks.
Sponsors
Hangzhou Normal University
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 50 and = 6 months, and confirmed by others; 3. 22-26 points for MMSE; 4. Comply with MCI and AD diagnostic standards; 5. Have sufficient visual and auditory resolution to accept neuropsychological tests; 6. Have a certain level of education, can read simple articles and write simple sentences in the past; 7. Have a stable caregiver; 8. Informed consent and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. People with vascular dementia or other causes of dementia, including VaD, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumors, bulbar palsy, epilepsy, chronic subdural hematoma and multiple sclerosis, with severe head A history of trauma with persistent neurological deficits or known brain structural abnormalities; 2. Have suffered from nervous system diseases (including stroke, myelitis, Parkinson's disease, epilepsy, etc.); 3. Taking pseudocholinergic or anticholinergic drugs and drugs that affect cognitive function at the same time; 4. Depression, schizophrenia and other mental illnesses; 5. Alcoholics, long-term use of antipsychotic drugs, history of severe head trauma; 6. Cannot cooperate with cognitive function testers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADAS-cog;ADCS-ADL; | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE;MoCA;CIBIC-plus; | — |
Countries
China
Contacts
Public ContactXiao Guomin
Hangzhou Normal University
Outcome results
None listed